CONTEXT: Lung carcinoma is the result of sequential accumulation of genetic and epigenetic changes. Lung adenocarcinoma is a heterogeneous disease with diverse somatic mutations, and several of them include the so-called driver mutations, which may serve as "druggable" therapeutic targets. Thus, development of personalized approaches for the treatment of non-small cell lung carcinoma (NSCLC) mandates that pathologists make a precise histologic classification inclusive of routine molecular analysis of such tumors. OBJECTIVE: To address the molecular mechanisms underlying NSCLC and how this knowledge reflects the multidisciplinary approach in the diagnosis and management of these patients. We will also summarize the current available and investigational personalized therapies for patients with resectable early-stage, unresectable locally advanced, and metastatic NSCLC. DATA SOURCES: Peer-reviewed published literature and personal experience. CONCLUSIONS: There are multiple mechanisms involved in the pathogenesis of lung cancer, which operate in parallel and involve pathways of activation and inhibition of various cellular events. Further research is essential to characterize the histologic and mutational profiles of lung carcinomas, which will ultimately translate into improved and more personalized therapeutic management of patients with lung cancer.
CONTEXT: Lung carcinoma is the result of sequential accumulation of genetic and epigenetic changes. Lung adenocarcinoma is a heterogeneous disease with diverse somatic mutations, and several of them include the so-called driver mutations, which may serve as "druggable" therapeutic targets. Thus, development of personalized approaches for the treatment of non-small cell lung carcinoma (NSCLC) mandates that pathologists make a precise histologic classification inclusive of routine molecular analysis of such tumors. OBJECTIVE: To address the molecular mechanisms underlying NSCLC and how this knowledge reflects the multidisciplinary approach in the diagnosis and management of these patients. We will also summarize the current available and investigational personalized therapies for patients with resectable early-stage, unresectable locally advanced, and metastatic NSCLC. DATA SOURCES: Peer-reviewed published literature and personal experience. CONCLUSIONS: There are multiple mechanisms involved in the pathogenesis of lung cancer, which operate in parallel and involve pathways of activation and inhibition of various cellular events. Further research is essential to characterize the histologic and mutational profiles of lung carcinomas, which will ultimately translate into improved and more personalized therapeutic management of patients with lung cancer.
Authors: Xiao-Qin Li; Jin Ren; Ping Chen; Yu-Jiao Chen; Min Wu; Yan Wu; Kang Chen; Jian Li Journal: Acta Pharmacol Sin Date: 2018-05-31 Impact factor: 6.150
Authors: Christine M Lusk; Donovan Watza; Greg Dyson; Douglas Craig; Valerie Ratliff; Angela S Wenzlaff; Fulvio Lonardo; Aliccia Bollig-Fischer; Gerold Bepler; Kristen Purrington; Shirish Gadgeel; Ann G Schwartz Journal: Clin Cancer Res Date: 2019-04-12 Impact factor: 12.531
Authors: Julian C Schink; Julia R Trosman; Christine B Weldon; Kalliopi P Siziopikou; Gregory J Tsongalis; Alfred W Rademaker; Jyoti D Patel; Al B Benson; Edith A Perez; William J Gradishar Journal: J Natl Cancer Inst Date: 2014-09-12 Impact factor: 13.506
Authors: Rime Abbas; Karen S McColl; Adam Kresak; Michael Yang; Yanwen Chen; Pingfu Fu; Gary Wildey; Afshin Dowlati Journal: Cancer Med Date: 2015-01-09 Impact factor: 4.711
Authors: Kamila Wojas-Krawczyk; Paweł Adam Krawczyk; Rodryg Adam Ramlau; Justyna Szumiło; Jerzy Kozielski; Ewa Kalinka-Warzocha; Maciej Bryl; Alina Knopik-Dąbrowicz; Lukasz Spychalski; Aleksandra Szczęsna; Ewelina Rydzik; Janusz Milanowski Journal: Contemp Oncol (Pozn) Date: 2013-12-19
Authors: Amy B Hall; Dave Newsome; Yuxin Wang; Diane M Boucher; Brenda Eustace; Yong Gu; Brian Hare; Mac A Johnson; Sean Milton; Cheryl E Murphy; Darin Takemoto; Crystal Tolman; Mark Wood; Peter Charlton; Jean-Damien Charrier; Brinley Furey; Julian Golec; Philip M Reaper; John R Pollard Journal: Oncotarget Date: 2014-07-30